Saint Prex, CH / Amsterdam, NL April 22, 2015 - A new educational resource for doctors and healthcare professionals will help improve knowledge and treatment of Inflammatory Bowel Disease (IBD). The Inflammatory Bowel Disease Resource Centre was developed by Elsevier, the journal Digestive and Liver Disease, and was made possible through an educational grant from Ferring Pharmaceuticals. The Inflammatory Bowel Disease Resource Center is a free online platform designed to increase healthcare professionals' knowledge of IBD.
The new IBD Resource Centre aims to give healthcare professionals the latest research and opinions on IBD, helping them treat patients more effectively. It is a unique source of peer-reviewed information, bringing together the latest research on IBD with insights and opinions from key thought leaders.
"IBD can really affect people's lives, and as healthcare professionals we can help limit the impact the disease has on them by treating it as effectively as possible," said Dr. Alessandro Armuzzi, editor of the Inflammatory Bowel Disease Resource Centre and leader of the IBD Unit at Complesso Integrato Columbus Catholic University, Rome, Italy. "We hope that this new resource will give healthcare professionals the information and guidance they need to help people with the disease."
As Resource Centre editor, Dr Alessandro Armuzzi selects, reviews and approves all the featured content. Healthcare professionals have free access to the peer-reviewed research featured on IBD Resource Centre , and can read articles and watch videos about IBD, increasing their understanding of the disease, and knowledge about its treatment.
"At Ferring, we think it's important that healthcare professionals have access to the latest peer-reviewed information," commented Pascal Danglas, MD, Executive Vice President and Chief Medical Officer, Ferring Pharmaceuticals. "We are pleased to add the Inflammatory Bowel Disease Resource Centre to the many educational resources Ferring sponsors."
"The new Resource Centre is a smart and innovative way of bringing the latest breakthroughs in IBD research from the journal Digestive and Liver Disease to a broad, international audience. It's an absolute privilege to work with Dr. Armuzzi on this endeavour. We greatly value the strong commitment from Ferring to this type of educational outreach," said Sybrand Boer Iwema, Elsevier Publisher for journal Digestive and Liver Disease.
###
For more information: http://www.IBD-RC.com.
About Digestive and Liver Disease
Digestive and Liver Disease is an International Journal of Gastroenterology and Hepatology, publishing papers on basic and clinical research in the field of gastroenterology and hepatology. http://www.journals.elsevier.com/digestive-and-liver-disease
About Ferring Pharmaceuticals
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit http://www.ferring.com
About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey-- and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries. http://www.elsevier.com
Media contact
Mareille Prevo
Elsevier
+31204853783
m.prevo@elsevier.com